SWShuqi Wang

Shuqi Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shuqi Wang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of care delivery models for knee osteoarthritis in primary healthcare settings: A systematic review and meta-analysis of randomized controlled trials

    by Hugo Pak-Yiu Fong, Shuqi Wang, Chunyi Wen, David Rabago, Christian Mallen, Regina Wing-Shan Sit

  • Open Access

    Feasibility and preliminary effectiveness of mindfulness-based stress reduction program on patients with nocturnal hypertension: a pilot randomized controlled trial

    by Shuqi Wang, Sze Nok Ng, Regina Wing Shan Sit, Chapman Cheuk Tung Ying, Shuk Yun Leung, Jinghao Han, Yue Kwan Choi, Kam Fai Chow, Wai Ho Chung, Benjamin Hon Kei Yip, et al.

    Wang S, et al. Clin Hypertens. 2026 ;32(1):e34. https://doi.org/10.5646/ch.2026.32.e34

  • Open Access

    The utility of common predictive models for detecting undiagnosed diabetes and prediabetes defined by HbA1c in a Chinese population

    by Shuqi Wang, Benjamin H.K. Yip, Paul K.M. Poon, Billy C.F. Chiu, Samuel Y.S. Wong, Juliana C.N. Chan, Eric K.P. Lee


  • Open Access

    Developing and validating a diagnostic threshold for central blood pressure in assessing cardiovascular risks

    by Shuqi Wang, Samuel Y S Wong, Benjamin H K Yip, Eric K P Lee

    Aims: This study aimed to establish an outcome-derived threshold for central blood pressure (cBP) and evaluate its clinical utility in stratifying cardiovascular (CVD) risk. Methods and results: A retrospective cohort study of 34 289 adults without prior CVD was conducted using the UK Biobank dataset. The primary endpoint was a composite of cardiovascular mortality and non-fatal cardiovascular events. Diagnostic threshold for cBP was developed by bootstrap and approximation methods, based on the current brachial BP. Cox regression models were employed to evaluate the clinical utility of diagnostic thresholds for cBP in predicting in CVD. A diagnostic threshold of 135 mmHg for central systolic blood pressure (SBP) corresponded to the threshold of 140 mmHg for brachial SBP. Simultaneous assessment of brachial and central SBP configurated following categories: brachial and central normotension (49.84%), isolated brachial hypertension (2.23%), isolated central hypertension (3.65%) and concordant brachial and central hypertension (44.28%). Compared with concordant normotension, hazard ratios for cardiovascular events were 0.81 (0.45, 1.44) for isolated brachial hypertension, 1.70 (1.23, 2.35) for isolated central hypertension and 1.51 (1.30, 1.76) for concordant hypertension. The inclusion of cBP improved model fit and discrimination for predicting CVD beyond brachial BP alone. Conclusion: This study established a diagnostic threshold of 135 mmHg for central SBP. Individuals with central HT exhibited elevated risks of CVD, regardless of brachial HT status. Incorporating central BP enhanced the prediction of CVD risk beyond traditional BP measurement alone.


  • Open Access

    Home blood pressure during night-time sleep – a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled trial

    by Eric Kam-Pui Lee, Shuqi Wang, Benjamin Hon-Kei Yip, Esther Yee-Tak Yu, Shuk-Yun Leung, Jinghao Han, Yue-Kwan Choi, Kam-Fai Chow, Wai-Ho Chung, Byran P. Yan, et al.

    This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.


  • Open Access

    Association of kidney function with dementia and brain pathologies: A community‐based cohort study

    by Jiao Wang, Shuqi Wang, Abigail Dove, Jie Guo, Xiuying Qi, David A Bennett, Weili Xu

    Background: Kidney function has been linked to cognitive function, but its relation to dementia and mechanisms underlying this relation remains unclear. We aimed to examine the association of impaired kidney function with dementia and brain pathologies.Method: Within Rush Memory and Aging Project, 1380 dementia‐free subjects (75.22% female; mean age: 79.42±7.61 years) at baseline were followed for up to 22 years. Blood samples were taken at baseline and serum creatinine was measured to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula. Kidney function dichotomized as normal (eGFR ≥ 60 mL/min/1.73 m2) or impaired (eGFR 2). Dementia, including Alzheimer’s dementia, was diagnosed following international criteria. During the follow‐up, 469 participants died and underwent autopsies for neuropathological assessment (including Alzheimer’s disease [AD], vascular, and other brain pathologies). Data were analyzed using Cox regression, Laplace regression, and logistic regression.Result: At baseline, 895 (64.86%) participants with normal kidney function and 485 (35.14%) with impaired. Over follow‐up (median [interquartile range]: 5 [2–9] years), 300 (21.74%) participants developed dementia, including 273 (19.78%) with Alzheimer’s dementia. In multi‐adjusted Cox regression, lower eGFR was does‐dependently associated with higher dementia risk (hazard ratio [HR] = 1.01, 95% confidence interval [CI]: 1.01–1.02, P = 0.003) and Alzheimer’s dementia risk (HR = 1.01, 95% CI: 1.00‐1.02, P = 0.002). Compared to normal kidney function, impaired kidney function was associated with a greater risk of dementia (HR = 1.49, 95% CI: 1.16–1.91) and Alzheimer’s dementia (HR = 1.45, 95% CI: 1.12–1.89). The median time to the development of dementia or Alzheimer’s dementia was 2.48 (95% CI: 0.36–3.03) or 2.56 (95% CI: 0.37–2.79) years shorter in people with impaired vs. normal kidney function, respectively. In brain pathology analysis, impaired kidney function was significantly related to higher burdens of cerebral amyloid angiopathy (odds ratio = 2.03, 95% CI: 1.23–3.35).Conclusion: Impaired kidney function is associated with an increased risk of dementia and Alzheimer’s dementia. Vascular mechanisms may underlie this association.

  • Stochastic functional linear models for gene-based association analysis of quantitative traits in longitudinal studies

    by Bingsong Zhang, Shuqi Wang, Xiaohan Mei, Yue Han, Runqiu Wang, Hong-Bin Fang, Chi-Yang Chiu, Jun Ding, Zuoheng Wang, Alexander F. Wilson, et al.

    International Press of Boston - publishers of scholarly mathematical and scientific journals and books


  • Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia

    by Kimberley Doucette, Mary‐Elizabeth Percival, Lacey Williams, Adrese Kandahari, Allison Taylor, Shuqi Wang, Jaeil Ahn, Judith E. Karp, Catherine Lai

    Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment‐related complications, as well as short‐term mortality and overall survival (OS) in 756 newly diagnosed AML patients. We conducted a retrospective multicenter study to examine treatment‐related complications and OS according to pretreatment serum albumin levels: normal albumin ≥3.5 g/dl, marked hypoalbuminemia p < 0.01). Similarly, 60‐day mortality rate was significantly higher in the hypoalbuminemia group (24.0%) and marked hypoalbuminemia group (45%) compared with normal albumin group (8.3%; p < 0.01). Patients with lower baseline albumin levels have increased treatment‐related morbidity and mortality, suggesting that pre‐treatment serum albumin is an important independent prognostic marker.


  • Open Access

    Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma

    by Noa Biran, Elli Gourna Paleoudis, Rena Feinman, David H. Vesole, Joshua Zenreich, Shuqi Wang, Jaeil Ahn, Meena Bansal, Scott Rowley, Michele Donato, et al.


  • Open Access

    Publication Rate and Characteristics of Lung Cancer Clinical Trials

    by Ghassan Al-Shbool, Hira Latif, Saira Farid, Shuqi Wang, Jaeil Ahn, Giuseppe Giaccone, Chul Kim

    Clinical trials play a crucial role in shaping the practice of medicine. Nonreporting of clinical trial results affects the validity of the literature and can negatively affect patient care. Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.1 Studies assessing reporting of clinical trial results in thoracic oncology are lacking. We sought to investigate the publication rate among registered lung cancer clinical trials.